Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|July 22, 2021

Biopharmaceutical Analysis 2021

Analytical techniques are essential to ensuring the quality, efficacy, and safety of biopharmaceutical products. Advances in instruments and methods are providing biopharmaceutical drug developers, process and manufacturing managers, and quality teams with the capabilities to identify potential problem areas quickly and effectively, and to expedite drug production. In this eBook, the editors share the new technologies and methodologies to analyze and characterize monoclonal antibodies, protein therapeutics, and emerging therapies, as well as best practices to ensure the integrity of analytical test data and evaluate cleaning validation efforts.


Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.